68Ga-PSMA

DRUG13 trials

Conditions

Adenoid Cystic CarcinomaHigh RiskMalignant MelanomaMalignant NeoplasmPet-ctProstate AdenocarcinomaProstate CancerProstate Cancer Metastatic

Early Phase 1

Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617

NCT04801264

Peking Union Medical College HospitalAdenoid Cystic Carcinoma

Start: 2020-09-01End: 2022-12-31Target: 40Updated: 2021-03-23

Phase 1

68 Ga-PSMA for High Risk Prostate Cancer

CompletedNCT04614363

The Methodist Hospital Research InstituteHigh Risk, Prostate Cancer

Start: 2020-10-13End: 2023-04-25Updated: 2023-08-28

Phase 2

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

NCT02282137

Ebrahim DelpassandProstate Cancer

Start: 2015-05-31End: 2023-12-31Target: 208Updated: 2020-08-19

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

CompletedNCT03396874

University of MichiganProstate Adenocarcinoma, Prostate Cancer, Prostate Cancer Metastatic +1

Start: 2018-02-09End: 2022-08-09Updated: 2023-11-03

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

TerminatedNCT03689582

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2018-11-13End: 2020-02-27Updated: 2022-01-05

PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

CompletedNCT05806853

IRCCS San RaffaeleProstate Cancer

Start: 2020-06-03End: 2022-10-05Updated: 2023-04-10

PET/MRI to Stage Prostate Cancer Patients

RecruitingNCT06484361

IRCCS San RaffaeleProstate Cancer

Start: 2020-09-09End: 2025-09-30Target: 50Updated: 2024-07-03

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

RecruitingNCT06560905

Royal Marsden NHS Foundation TrustMalignant Melanoma

Start: 2025-03-11End: 2025-12-31Target: 16Updated: 2025-07-01

Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pre-operative Lymph Node Assessment in Intermediate and High-risk Nonmetastasic Prostate Cancer

CompletedCTIS2024-516319-25-00

Centre Hospitalier Regional Et Universitaire De BrestProstate Cancer

End: 2025-12-15Target: 159Updated: 2025-04-30

Unknown Phase

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

CompletedNCT03453528

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSmCRPC or Advanced/Metastatic Solid Tumors, Prostate-specific Membrane Antigen

Start: 2017-07-04End: 2025-01-03Updated: 2025-01-08

Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma

NCT05006326

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyMalignant Neoplasm

Start: 2021-08-16End: 2023-12-31Target: 30Updated: 2023-02-14

Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617

NCT05170555

Peking Union Medical College HospitalRenal Cell Carcinoma

Start: 2021-12-01End: 2023-07-01Target: 40Updated: 2021-12-28

Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.

SuspendedNCT06355843

The First Affiliated Hospital of Anhui Medical UniversityPet-ct, Prostate Cancer

Start: 2022-04-28End: 2027-03-31Target: 50Updated: 2024-04-09

Related Papers

[<sup>68</sup>Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma.

2024-11-214 citations

Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma

PLoS ONE2022-11-117 citations

A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma

EJNMMI Research2022-08-1919 citations

PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study

Journal of Nuclear Medicine2021-10-0730 citations